Van den Berghe, N., Verstockt, B., Tops, S., Ferrante, M., Vermeire, S. and Gils, A. (2019) Immunogenicity Is Not the Driving Force of Treatment Failure in Vedolizumab-Treated Inflammatory Bowel Disease Patients. Journal of Gastroenterology and Hepatology, 34, 1175-1181.
https://doi.org/10.1111/jgh.14584

has been cited by the following article:

• TITLE: Progress in the Study of Inflammatory Bowel Disease Patients with Primary Non-Responsiveness

  AUTHORS: Yixue Liu, Xiaoping Tan

  KEYWORDS: Inflammatory Bowel Disease, Primary Non-Responsiveness, Anti-Tumor Necrosis Factor

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.1, January 15, 2024

  ABSTRACT: Inflammatory bowel disease (IBD) is a group of chronic, nonspecific intestinal inflammatory disorders characterized by localized and systemic inflammation. The use of biologic agents in the treatment of IBD patients is widespread, and the occurrence of primary non-responsiveness during treatment is also significant. This review briefly summarizes the possible reasons for primary non-responsiveness in IBD patients, as well as predictive markers and current strategies to address it, providing a theoretical reference for early identification and management of IBD patients who do not respond to treatment.